John Bertrand on FDA Approval, CMS Reimbursement, and AI Healthcare Reality

Guest: John Bertrand, former Digital Diagnostics Episode DescriptionJoe Grogan sits down with John Bertrand, a veteran healthcare technology executive who scaled Digital Diagnostics to 75 health systems and achieved the first FDA approval and CMS reimbursement for an autonomous AI diagnostic device without a physician in the diagnostic loop. Bertrand reveals the harsh realities of bringing AI innovation to market: FDA and CMS regulatory frameworks are built for traditional medical devices and physician-driven care, not autonomous AI diagnostics. The conversation covers the shocking CMS reimbursement draft that came in 40-60% below cost of goods sold, the massive first-mover disadvantage in regulated medical device AI, and why reimbursement is the true gating factor for adoption—not clinical superiority. Bertrand explains how workflow integration and financial incentives matter far more than being clinically better. The episode explores the massive gap between what entrepreneurs think should happen with new innovations and the regulatory reality. He concludes with a sobering assessment: if building diagnostic AI again, he would choose supply chain automation instead because the regulatory and reimbursement headwinds are so significant they punish innovators. Where AI is actually making an impact today is patient-facing triage agents, administrative automation, and revenue cycle management—areas with far less friction.KEY TIMESTAMPS0:40 Joe introduces John Bertrand and his healthcare tech background1:28 John clarifies he recently left Digital Diagnostics for supply chain work2:40 John's career: 13 years at Epic Systems across multiple roles6:10 What does Digital Diagnostics' AI device do? Automating retinal imaging7:56 First FDA approval and first CMS reimbursement for autonomous AI diagnostic9:02 Joe's threshold question: shouldn't better innovation be easily adopted?9:50 Reality: workflow integration and reimbursement matter more than clinical quality11:50 The adoption curve: all successful FDA-approved AI devices have CMS reimbursement14:10 FDA experience: desire to help but frameworks built for old technology15:40 FDA scrutiny on AI exceeds scrutiny on human clinicians18:05 FDA guidance changes every 6-12 months, creating constant pivoting and delays20:08 Shifting to CMS: the shocking draft reimbursement story20:45 Draft came in at $10 per test, needed $30+ to be viable22:42 Four months of negotiations with CMS to shift value argument24:40 Process not codified: each company follows unique regulatory path28:04 Six years at Digital Diagnostics: was it worth it?28:44 John would not recommend diagnostic AI to new founders33:02 Turning down multiple diagnostic AI opportunities post-Digital Diagnostics34:19 AI hype vs reality: where are patients actually seeing life improvements?34:19 Patient-facing triage agents are the second inning of real AI opportunity36:25 Reimbursement for chat-based triage: who gets paid?38:23 Autonomous vs assistive AI: the regulatory gap that exists40:31 Could Digital Diagnostics have done physician-in-loop from the start?41:33 Real opportunity: clinical practices deploying their own AI42:20 State licensing nightmare: deploying AI across 50 states44:55 The real concern: RCM automation becoming a zero-sum AI bot battle45:20 Dead Internet Theory applied to healthcare revenue cycle47:38 Closing: a tour de force on AI healthcare realityKey TopicsAI in healthcare, FDA approval process, CMS reimbursement, autonomous AI diagnostics, Digital Diagnostics, diabetic retinopathy, regulatory frameworks, first-mover disadvantage, workflow integration, reimbursement strategy, patient-facing AI, healthcare innovation, regulatory friction, adoption barriers, state licensing, RCM automation, healthcare AI reality About the GuestJohn Bertrand is a veteran healthcare technology executive with over 20 years of experience. He spent 13 years at Epic Systems in analyst, product manag